Business
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat
About this update from Pfizer, Inc.
[{"type":"image","alt":"Adaptive Biotechnologies","displaySize":"","headline":null,"caption":"Adaptive Biotechnologies","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/e5ea8b7702560ef74ea125795697d8b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8o2FzIfUzzjFPRTmRJLvKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e5ea8b7702560ef74ea125795697d8b2","width":300,"height":169}},"lazy":false},{"type":"text","content":"A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis","length":105,"tagName":"p"},{"type":"text","content":"A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications","length":145,"tagName":"p"},{"type":"text","content":"SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced two non-exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage Adaptive’s proprietary T-cell receptor (TCR) discovery capabilities and large-scale immune receptor antigen mapping data.","length":464,"tagName":"p"},{"type":"text","content":"Discovering disease-causing TCRs in rheumatoid arthritis","length":56,"tagName":"p"},{"type":"text","content":"Adaptive has identified autoreactive or ‘offender’ TCRs that could potentially cause disease in patients with autoimmune indications.","length":133,"tagName":"p"},{"type":"text","content":"Pfizer will utilize Adaptive’s immune medicine platform to identify disease-causing TCRs as potential therapeutic targets in rheumatoid arthritis (RA). Under this agreement, Adaptive will apply its platform to Pfizer’s clinical samples to identify the subset of common TCRs that are significantly enriched in RA patients. Pfizer will use these data to accelerate its research and development of potential therapeutic candidates for RA.","length":435,"tagName":"p"},{"type":"text","content":"Licensing Adaptive’s TCR-antigen datasets","length":41,"tagName":"p"},{"type":"text","content":"Adaptive has generated what it believes is the largest and hi...